Cyclins are major cell cycle regulators which role in malignant transformation remains controversial. In this report we describe a new mechanism of cyclin oncogenic activation. We demonstrate that an altered form of cyclin A2 (S2A) which N-terminal part is replaced by the hepatitis B virus envelope protein transforms normal rat kidney cells and cooperates with ras to transform rat embryo ®broblasts. In contrast, neither the viral moiety, nor a full length or N-terminally deleted cyclin A2 show these oncogenic properties. S2A oncogenicity arises from its binding to cyclin dependent kinases, since mutation in the MRAIL sequence abolishes transformation and correlates with an abnormal cellular localization in the endoplasmic reticulum membrane. Together, these results implicate modi®cation in the cellular distribution of a cell cycle regulator as a mechanism of virally-induced transformation.
Introduction
Normal progression through the mammalian cell cycle occurs by the transient activation of protein kinase complexes, each consisting of a cyclin regulatory subunit and a cyclin dependent kinase (CDK) catalytic component (Pines, 1993; Sherr, 1994; Wuaring and Nurse, 1996; Nasmyth, 1996) .
The loss of cell cycle control is associated with oncogenesis and it has been suggested that cell cycle regulatory proteins, such as cyclins, CDKs, and their inhibitors (CKIs), may play a direct role in transformation and act as oncogenes (Hunter and Pines, 1994; Sherr, 1996) . Support for this hypothesis comes from the observed up-regulation of cyclins and CDKs gene expression in tumors and tumor cell lines and from in vivo and in vitro data which suggest that cyclins involved in G1 and G1/S transitions (cyclins D and E respectively) do, under certain circumstances, have an oncogenic potential (Wang et al., 1994; Hinds et al., 1994; Lovec et al., 1994; Mumberg et al., 1996; Bortner and Rosenberg, 1997) . This is in contrast with the data obtained to date for cyclin A2, which acts downstream of cyclins D and E in two distinct cell cycle transitions, namely the initiation and progression of S phase and the G2/M transition, in association with CDK2 and CDK1, respectively Pagano et al., 1992) . The ectopic expression of cyclin A2 in vitro shortens G1 Resnitzky et al., 1994) and abrogates adhesion dependency for S phase entry (Guadagno et al., 1993) . In vivo, overexpression of cyclin A2 in the mammary gland of transgenic mice results in the induction of nuclear abnormalities and increased apoptosis (Bortner and Rosenberg, 1995) . In addition, cyclin A2 is a target of viral oncogenes such as E1A, E7, or SV40 T antigen, that activate the cyclin A2 promoter (Buchou et al., 1993; Zerfass et al., 1996) and interact with cyclin A2 in multiproteic complexes also containing p107 and E2F (Nevins, 1994) . However, despite these reports, there is no direct evidence for the transforming capacity of cyclin A2 and in general, although there is a strong correlation between an increased activity of cyclin/CDK complexes and neoplastic transformation, the evidence that this activity plays a causative role in oncogenesis is still circumstantial.
We have previously reported the existence of an altered form of cyclin A2 in an hepatitis B virus (HBV)-associated hepatocarcinoma (Wang et al., 1990 . HBV is an important etiological factor of liver cancer and there are several observations which point to a direct eect of the viral genome in transformation. The integration of the HBV genome is a frequent event in human hepatocarcinoma and induces chromosomal instability, translocations and deletions at the site of insertion (Rogler et al., 1992; Marchio et al., 1997) . This integration also allows persistence of rearranged and truncated viral genomes that code for transactivators (the X protein of HBV (HBx) and truncated forms of the middle surface antigen) (Henkler and Koshi, 1996; Caselmann, 1996; Hildt et al., 1996) . In isolated tumors, insertion occurs in genes coding for proteins with an essential role in cell proliferation or dierentiation, namely the retinoid acid receptor (Dejean et al., 1986; de TheÂ et al., 1987) , cyclin A2 (Wang et al., 1990 and mevalonate kinase (GraeÈ f et al., 1994 (GraeÈ f et al., , 1995 or in genes coding for the epidermal growth factor receptor (Zhang et al., 1992) and a carboxypeptidase (Pineau et al., 1996) the impact of which remains to be clari®ed. This contrasts strikingly with the Woodchuck animal model, where insertion of the Woodchuck hepatitis virus (WHV) into the N-myc2 and c-myc oncogenes in liver cancers is a frequent event of which the transforming eect has been well established (Buendia, 1992) .
Insertion of the HBV DNA into the cyclin A2 gene generates a chimaeric RNA initiated at the viral major surface gene promoter . This mRNA comprises a 3'-truncated part of the PreS2/S sequence (PreS2/S t ) fused to a 5' truncated cyclin A2 (dCycA) sequence. There is an open reading frame which encodes a fusion protein (referred from now as S2A in this manuscript) in which the ®rst 152 amino acids of cyclin A2 have been replaced by the ®rst 156 amino acids of the viral middle surface antigen, leaving the cyclin box and the MRAIL motif known to be essential for binding to CDKs intact. The analysis of S2A provides therefore an excellent model with which to investigate the involvement of a cyclin in carcinogenesis for the following reasons: (1) the cyclin A2 moiety has lost the N-terminal degradation signal present in the wild type cyclin A2 and is hence undegradable . The importance of controlling the degradation of cell cycle regulators for normal cell cycle progression has been well documented, in particular for cyclins A and B and the CKI p27, which rate of degradation is increased in aggressive forms of colon and breast cancers (Loda et al., 1997; Porter et al., 1997) . In contrast, there is no report on the implication of cyclin degradation in the proliferation of cancer cells in vivo; (2) the viral PreS2/S t moiety encodes for a transmembrane transactivator (Meyer et al., 1992; Hildt et al., 1993) . It is therefore plausible that it would target cyclin A2 to an abnormal cellular compartment. Cyclin A2 is a nuclear protein from late G1 (Pines et al., 1991) , but some reports point to an additional cytoplasmic fraction (Carbonaro-Hall et al., 1993; Castro et al., 1994) . The actual signi®cance of this observation is not known, and in particular its putative contribution to abnormal cellular proliferation has never been addressed; (3) despite numerous studies, whether or not cis-activation of a single cellular gene by HBV DNA insertion can induce cell transformation is still an open question. The tumor we have investigated is particularly informative in this respect since it has developed in the absence of any signi®cant chronic hepatitis and the viral DNA insertion is present as a single integrant in clonally proliferating liver cells.
The present study demonstrates the oncogenic property of S2A which requires an intact MRAIL motif, hence binding to a CDK is implicated in transformation. We also show that the cyclin A2 has been targeted to the endoplasmic reticulum membranes through its fusion with the viral protein. This oncogenic eect was observed neither with the PreS2/ S t moiety, nor with a full length or N-terminally deleted normal cyclin A2. Taken together, these results implicate the modi®cation in the cellular distribution of a cell cycle regulator such as cyclin A2 upon HBV DNA integration as a new mechanism of neoplastic transformation.
Results
Stable expression of S2A induces transformation and tumorigenicity of immortalized normal rat kidney (NRK) cells
We ®rst investigated the phenotypic eects of stable S2A expression in NRK cells. Thus, using the inducible pOPRSVILacI expression vector, we generated NRK (1) Neo, CycA and S2A clones hybridized with full length cyclin A2 (CycA) and PreS2/S t probes. The size of the endogenous cyclin A2 (1.7 and 2.7 kb) and exogenous S2A and CycA bands (2.2 kb) are indicated. (2) PreS2/S t clones hybridized with a PreS2/S t probe to show the 1.1 kb exogenous band. RNA from dCycA-8 and S2A-7 clones are used as negative and positive controls respectively. (3) dCycA clones hybridized with a TK-polyA probe corresponding to nucleotides 1500 ± 1600 from cyclin A2 and the TK-polyA sequence from the expression plasmid, to show the 1.7 kb exogenous band. RNA from CycA clone is used as control. (4) NRK clones transfected with S2Am hybridized with a PreS2/S t probe, showing the 2.2 kb speci®c mRNA clones expressing S2A, the normal cyclin A2 (CycA) and the viral (PreS/S t ) or the cyclin (N-terminally deleted cyclin A, dCycA) S2A domains ( Figure 1a ). Despite ®ve independent transfections, we only achieved establishment of one clone expressing normal full length cyclin A2. For further studies we selected the CycA expressing clone and four S2A (S2A-6, 7, 8, 15) , two PreS2/S t (PreS2/S t -1 and 2) and two dCycA (dCycA-4 and 8) expressing clones. Figure 1b shows the RNA expression pattern obtained with these various constructs. The levels of RNA expression were low compared to endogenous cyclin A2 and were not increased upon IPTG addition (not shown). Thus, the pOPRSVILacI promoter acted in fact in these experiments as a leaky non-inducible and weak promoter, allowing us to obtain such stable expressing clones while strong promoters were inecient (data not shown).
No phenotypic dierence was noticed in CycA, PreS2/S t and dCycA clones compared to control nontransfected NRK cells or cells transfected with the empty expression vector (Neo). These cells exhibited a well-spread morphology, an organized growth pattern and density-dependent growth inhibition ( Figure 2a and data not shown). In contrast, clones S2A-6, S2A-15 and, to a lesser extent, S2A-7 showed a spindleshaped cell morphology, highly disordered growth pattern and absence of density-dependent growth inhibition (Figure 2b ± d) . Clone S2A-8 was the only S2A expressing clone which did not show signi®cant changes ( Figure 2e ).
We analysed the growth rates of the dierent clones in monolayer culture. The results are summarized in Table 1 . Clones expressing S2A reached a higher saturation density compared to PreS2/S t , dCycA and CycA expressing clones. They also showed a shorter doubling time (except clone S2A-8).
Morphological transformation generally correlates with an alteration of actin stress ®ber organization (Boschek et al., 1981) and a decrease in the expression of tropomyosin (TM) 1 and 2 isoforms (Matsumura et al., 1983; Masuda et al., 1996) . Clones Neo, CycA, PreS2/S t and dCycA showed well-organized actin bundles ( Figure 3a : 1 ± 3, 9). In contrast, clones S2A-6 and S2A-15 showed much less evident actin stress ®bers and areas of membranes ruing ( Figure 3a : 4 ± 5, 10) similar to those found in oncogene-transformed NRK cells (Masuda et al., 1996) . Clone S2A-7 showed a pattern of staining intermediate between these two groups and clone S2A-8 was similar to controls (Figure 3a: 6 ± 7). As shown in Figure 3b the expression of TM 1 and 2 was markedly decreased in all the S2A expressing clones. The ability to form tumors in athymic mice is a hallmark of neoplastic transformation. Clones expressing the dierent constructs were inoculated into nude mice. As shown in Table 1 , clones Neo, PreS2/S t , dCycA and CycA did not induce any tumor. In contrast, 11 out of 12 mice inoculated with S2A-15 and 10 out of 12 inoculated with S2A-6 showed tumors (®brosarcomas) with a latency period of 3 ± 4 months. In mice injected with S2A-7 we observed the appearance of small (3 mm), subcutaneous, cartilaginous nodules 3 ± 8 weeks after injection, that later regressed. The appearance of small cartilaginous nodules has been described in mice injected with REF cells transfected with the activated Ha-ras oncogene (Land et al., 1983) .
S2A cooperates with the Ha-ras gene to transform rat embryo ®broblasts (REF)
We then analysed the capacity of S2A and the various controls to transform cells in primary culture, alone or in combination with Ha-ras. As a positive control, REF were cotransfected with Ha-ras and c-myc expressing plasmids. As shown in Table 2 , in two independent experiments, foci of transformed cells were observed in the positive control ( Figure 4b ). CycA, dCycA and PreS2/S t did not induce the appearance of any focus, either alone or after co-transfection with Ha-ras ( Figure 4a ). In contrast, foci were clearly detected, albeit in low number, in cells expressing S2A and Ha-ras (Figure 4c ). These results were further supported by the analysis, upon selection with G418, of the percentage of transformed colonies generated by these various constructs (Table 2 and Figure 4d and e).
In summary, S2A induces morphological transformation and altered growth control in NRK clones (spindle-shaped cells with disrupted actin bundles, decreased expression of TM 1 and 2, high saturation densities, disordered growth and induction of tumors in nude mice) and cooperates with Ha-ras to induce foci formation in REF. Conversely, CycA, PreS2/S t and dCycA do not alter NRK cell morphology and growth properties, are not tumorigenic in nude mice and do not cooperate with Ha-ras to induce foci formation in REF. Hence, S2A has a unique tranforming potency which is not shared by its viral and cyclin domains analysed separately.
S2A-induced transformation requires its binding to a CDK
We next attempted to analyse the mechanisms implicated in S2A-induced transformation. Our previous study has demonstrated that S2A is not degraded . In the present study, we examined whether the binding of S2A to a CDK was implicated in transformation. It has been shown (Kobayashi et al., 1992 ) that a point mutation in the cyclin A2 box (R197A in the MRAIL motif) is sucient to abolish its ability to bind to CDK2. We constructed a S2A mutant (S2Am) carrying this point mutation and studied the phenotype of four NRK clones (S2Am 1, 15, 17, 19) stably expressing S2Am. All these clones showed a¯at, normal cell morphology with normal actin bundles (Figures 2f and 3a: 8), normal expression of TM (Figure 3b ) and normal saturation densities and population doubling times (Table 1) . Only one of the four clones (S2Am-15) induced tumors in nude mice which may result from additional mutations upon selection of this clone (Table 1) . S2Am did not cooperate with Ha-ras to induce foci formation in REF (Table 2) . These data therefore demonstrate that S2A binding to a CDK is essential for its oncogenic eect.
S2A shows transactivating activity
It has been previously shown that truncated PreS2/S sequences code for transactivators KekuleÂ et al., 1990) . This property is generated by 3' truncation of the HBV PreS2/S gene in the socalled`trans-activity ON' (TAO) region. Polypeptides truncated between residues 76 and 194 retain this transactivator activity (Lauer et al., 1992) . As the PreS2/S t sequence present in S2A contain residues 1 ± 156, S2A might act as a transactivator. Figure 5 shows that both S2A and S2Am are indeed stronger transactivators than PreS2/S t .
S2A is localized in the endoplasmic reticulum
Using several anti-PreS2/S and anti-CycA antibodies, we were unable to show convincingly the S2A protein in NRK clones by either Western blot or immunouorescence (data not shown). S2A levels are presumably undetectable with the available antibodies, as was also found in the original tumor in which S2A was described . Therefore, to analyse the cellular localization of S2A, we fused our various constructs with the green¯uorescent protein (GFP) and expressed them transiently in COS cells.
As observed previously (Ogawa et al., 1995) , GFP was homogeneously localized in the cytoplasm and in We characterized the cytoplasmic localization of GFP-PreS2/S t , GFP-S2A, GFP-S2Am and as a negative control GFP-dCycA using two anti-ER antibodies. Similar results were obtained with both antibodies. As shown in Figure 6b : 1, GFP-S2A staining overlapped signi®cantly with ER staining, con®rming an ER localization of S2A. The same result was obtained with GFP-S2Am (data not shown). In contrast with previous reports, GFP-PreS2/S t did not co-localize signi®cantly with the ER (Figure 6b : 2) as did not GFP-dCycA (Figure 6b: 3) . From these observations we conclude that S2A has been targeted to the ER by the fusion of the cyclin A2 and PreS2/S t domains.
S2A is a transmembrane protein
In order to investigate the ER membrane association of S2A, cell free translations of plasmids coding either dCycA, PreS2/S t , S2A or S2Am were carried out in the presence of microsomes derived from the rough ER that were then sedimented by centrifugation (Figure 7a ). While dCycA was seen exclusively in the supernatant (S) or cytoplasmic fraction, PreS2/S t , S2A and S2Am all predominantly pellet with the membranes (P).
To determine the transmembrane topology of S2A in the ER membrane, cell-free translation reactions were carried out in the presence and absence of added microsomal membranes followed by protease protection analysis of translation products in the presence or absence of added detergent (added to disrupt the lipid bilayer) and subsequent immunoprecipitation with either anti-HBsAg or anti-Cyclin A antibodies. These experiments showed that S2A and S2Am are transmembrane proteins with the same topology. As shown in Figure 7b for S2Am, when translated in the absence of microsomal membranes a single *53 kDa band was observed which was both HBsAg and CycA-immunoreactive (lanes 1 and 2, position indicated by 7CHO). Whem membranes were present during translation, the predominant translation product showed a shift in mobility (compare lanes 3 and 4 to lanes 1 and 2) which is consistent with glycosylation of the protein. Indeed, this band (indicated by +CHO) was drastically reduced when translations were carried out in the presence of an acceptor peptide which acts as a competitive inhibitor of N-linked glycosylation (data not shown). When translation products obtained in the absence of membranes were subjected to proteolysis, the 7CHO fusion protein was completely degraded (lanes 5 and 6). However, when protease was added to translation products obtained in the presence of membranes only a HBsAg-immunoreactive protected fragment was seen (lane 7, arrow), while no CycA-immunoreactive fragments were visible (lane 8). The protected fragment represents a glycosylated fragment of HBsAg since its mobility was increased when translations carried out in the presence of both glycosylation acceptor peptide and microsomes were subjected to proteolysis (data not shown). The addition of the non-ionic detergent Triton X-100, resulted in complete degradation of the glycosylated fusion protein by the added protease (compare lanes 7 and 9). These data suggest that S2Am and S2A spans the ER membrane with portion of the PreS2/S t domain in the ER lumen (see diagrams b and d in Figure 7b ) since it is both glycosylated and protected from exogenous protease; the dCycA domain appears to be exposed in the cytoplasm since it is neither glycosylated nor protected from protease (see diagrams b and d in Figure  7b ).
Discussion
The integration of the HBV genome into the cyclin A2 gene in a human liver cancer has led to the fusion of a viral envelope protein to the central and C-terminal domains of cyclin A2. This hybrid protein (S2A) provides a unique paradigm with which to dissect the phenotypic properties of a stabilized cyclin inappropriately targeted to an abnormal, cytoplasmic, cellular compartment and to correlate these results with human carcinogenesis. It also oers the ®rst de®nite evidence for a direct eect of HBV DNA integration in human liver carcinogenesis. In the present report, we have demonstrated the transforming capacity of S2A and correlated this transformation with its binding to CDK 
Restriction sites are underlined. Start codon is shown in bold and its cytoplasmic localization in the membranes of the ER. These data implicate intra-cellular tracking of cell cycle regulators, such as cyclins, in their oncogenic activation.
Previous reports have established that, upon ectopic expression, normal cyclins D1 and E, involved in the G1 and G1/S transitions, can show oncogenic properties (Hinds et al., 1994; Lovec et al., 1994; Mumberg et al., 1996) . It has also been shown that inappropriate activation of a G2/M regulator, namely cdc25C, can cooperate with Ha-ras and transform REF (Galaktionov et al., 1995) . Our data demonstrate that a cyclin involved in the onset and progression of S phase can also be directly implicated in oncogenesis. However, in marked contrast with cyclins D1 and E, the oncogenic potential of cyclin A2 is directly correlated with modi®cation of its structure. Thus, NRK clones expressing either normal cyclin A2 or the truncated cyclin A2 (dCycA) sequence present in S2A, showed no evidence of transformation. On the same line, such constructs did not cooperate with Ha-ras in the REF assay. Our results therefore demonstrate that neither the ectopic expression, nor stabilization of cyclin A2 is sucient to induce malignant transformation, in agreement with previous reports. In vitro, ectopic expression of a normal cyclin A2 accelerates entry into S phase both in a rat ®broblastic cell line and in the fully transformed HeLa cell line Resnitzky et al., 1995) and also abrogates adhesion dependency for entry into S phase of NRK cells (Guadagno et al., 1993) . In vivo, overexpression of cyclin A2 in the mammary gland of transgenic mice, either in a normal form or with an N-terminal deletion, induces some dysplastic nuclear abnormalities. However, the main feature of this study was an increase in apoptosis of mammary cells without any tumor development (Bortner and Rosenberg, 1995) . Of note, this phenotype was only clearly identi®ed in those animals which expressed the N-terminally deleted cyclin A2, and was markedly enhanced in transgenic animals expressing both the N-terminally deleted cyclin A2 and CDK2, implicating the cyclin A2/ CDK2 kinase activity in this eect. It is interesting to note that, in these experiments, the cyclin A2 Nterminal deletion was identical to that present in S2A. Altogether, these various in vitro and in vivo observations demonstrate that normal or N-terminal deleted, stabilized, form of cyclin A2 do not induce a fully transformed phenotype and thus cannot solely account for the phenotypic eects of S2A.
A major feature of S2A is the replacement of the Nterminal region of cyclin A2 by a viral envelope sequence which might therefore also participate in its biological properties. Some reports have shown that viral insertion in liver cancers might generate 3' deleted forms of the HBV envelope sequence PreS2/S (PreS2/ S t ) that code for transactivators (Henkler and Koshy, 1996; Caselmann, 1996; Hildt et al., 1996) . A`transactivity-ON' (TAO)-region was de®ned within the PreS2/S sequence (Lauer et al., 1992) which is retained in the PreS2/S t moiety of S2A and is functional, as demonstrated in the present study. One might therefore hypothesize that this transactivating activity may participate in S2A transforming capacity. Our study shows however, no evidence for transformation upon expression of PreS2/S t , a ®nding in agreement with previous reports (Luber et al., 1996) . In addition, an S2A mutant (S2Am) incapable of binding to CDKs has transactivator activity without transforming capacity. Therefore, although we do not exclude a contribution of the transactivating capacity of PreS2/S t sequences to the transformed phenotype, our data demonstrate that it is the fusion between the viral and cyclin moieties which drives the oncogenic activity of S2A.
What mechanisms are involved in this oncogenic activation? An important observation in our study has been the demonstration that a mutation in the MRAIL cyclin A2 sequence abolishes the transforming activity of S2A. The MRAIL sequence has been shown to be critical for the binding of cyclin A2 to CDKs (Kobayashi et al., 1992) . Our data therefore imply that binding of S2A to a CDK is essential for induction of full transformation. We also show that the targeting of this truncated and stabilized cyclin A2 to the membranes of the ER correlates with the acquisition of the transformed phenotype. S2A is a transmembrane glycoprotein that colocalizes with the ER and shows the PreS2/S t moiety glycosylated and exposed to the lumenal side and the cyclin A2 moiety mostly exposed to the cytosolic side of the ER membranes. It has been previously reported that PreS2/S t code for proteins localized in the ER and it is still debated whether or not these proteins are glycosylated and whether their transactivating eect depends on their protrusion into the cytosolic side of the ER complex (Meyer et al., 1992; Hildt et al., 1993) . In this study we show that PreS2/S t and S2A code for glycosylated transactivators that accumulate in dierent subcellular compartments. In contrast with previous reports, the protein coded by PreS2/S t seems to accumulate in the golgi complex as it has been shown for the small hepatitis B surface antigen (HBsAg) (Huovila et al., 1992) . By contrast, S2A accumulates in the ER suggesting that the fusion of the cyclin A2 has also modi®ed the localization of the viral protein.
Having established the contribution of both the CDK binding activity and the ER membrane localization of S2A to the oncogenic activity, it is possible to propose two main, though non-exclusive, mechanisms of transformation. First, one might envisage the phosphorylation by a CDK of inappropriate, cytosolic target(s). The existence of a cytosolic fraction of cyclin A2 has been raised in a few studies. Cyclin A2 associated H1 kinase activity has been reported in the endosomal as well as ER fractions of rat liver cells and is increased in vivo during liver regeneration (Castro et al., 1994; Verges et al., 1997) . It has been suggested that the kinase activity associated with cytosolic cyclin A2 might be implicated in the inhibition of in vitro intra-Golgi transport (Stuart et al., 1993; Mackay et al., 1993) and in the inhibition of the in vitro fusion of endocytic vesicles (Woodman et al., 1993) , in contrast with previous reports (Thomas et al., 1992) . The actual implications of these ®ndings for cell cycle progression have however not been established. Our results would imply that phosphorylation of some targets in the cytoplasm might in fact participate in transformation. We failed however, to conclusively demonstrate an H1 kinase activity of in vitro translated S2A (data not shown). This suggests that, although binding to a CDK is critical for the transforming eect of S2A, activation of the CDK kinase may not be the main mechanism involved. A second hypothesis one may raise would therefore rather implicate the sequestration of a CDK from its normal target sequence, due to its binding to S2A. With the same view, one might also envisage local formation of CDK and CKI containing complexes which would modify their cellular distribution. Recent reports have emphasized the importance of the subcellular dynamic localization of molecules such as CDKs for normal cell cycle control (Heald et al., 1993; Bresnahan et al., 1996) and CKIs (LeBaer et al., 1997; Reynisdottir and Massague, 1997) . Our present study expands this issue and shows the impact in carcinogenesis of an intracellular redistribution of a cyclin.
Finally, our observation oers relevant information for human carcinogenesis. With respect to HBV, this is a ®rst case where it has been possible to de®nitely recapitulate transformation due to an HBV-cellular hybrid protein, synthesized from the cDNA originally identi®ed in a tumor. In addition, our report comes from a rare case where the tumor evolved from a monoclonal expansion containing the HBV DNA insertion into the cyclin A2 locus as the only integrant and which in turn developed in the absence of active chronic hepatitis, a major risk factor for this tumor. Our study therefore has oered a model which documents from an in vivo condition how an oncogenic eect can be obtained by driving a major cell cycle regulator to a cellular compartment dictated by the viral protein.
Materials and methods

Plasmid constructs
We modi®ed the Lac switch inducible mammalian expression system (Stratagene) by cloning the LacI repressor directly into the DraIII site of the insert expression vector (pOPRSVICAT). The HBV-Cyclin A (S2A) and human Cyclin A2 (CycA) cDNAs were ®rst cloned into BlueScript (pBS) (Stratagene), as well as the sequences corresponding to the HBV (PreS2/S t ) and the truncated Cyclin A (dCycA) moieties of S2A, that were cloned by PCR, using as template pBS-S2A. Primers used are shown in Table 3 and specify a NotI site used for cloning. The MRAIL motif in the cyclin box of S2A, was mutated to MAAIL by directed mutagenesis to give S2Am. The dierent inserts CycA, S2A, PreS2/S t , dCycA and S2Am ( Figure 1a) were cloned into the NotI site of the expression vectors pOPRSVICAT and the modi®ed pOPRSVILacI. The coding capacity of all constructs was con®rmed by sequencing (ESGS, France) and in vitro transcription-translation (TNT coupled reticulocyte system, Promega).
To express the GFP fusion products we used the mammalian expression vector pBK-CMV (pBK) (Stratagene). The S65T mutated GFP insert from pRSET-GFP plasmid (kindly provided by Dr Tsien), was directly subcloned into the BamHI site of pBK and used as template to obtain by PCR the dierent GFP fusions (see Table 3 for primers sequence). A 5' primer specifying a SacI site upstream the start (GFP 5') and two dierent 3' primers with a SacII site (GFP 3'-1) or a NotI site (GFP 3'-2) were used. In both cases, the stop codon of GFP was eliminated after ampli®cation. We incorporated a SacII site in frame with the ATG of S2A and a NotI site in frame with the ATG of CycA and we used them to obtain GFP-S2A and GFPCycA fusions respectively. These fusions were cloned as SacI/ HindIII fragments in pBK-CMV. To obtain GFP-PreS2/S Western blot assay for tropomyosin NRK cells grown to 90% con¯uency were lysed and 5 mg of the solubilized proteins were electrophoresed and blotted for the detection of tropomyosin as described (Masuda et al., 1996) .
Test for tumorigenicity in nude mice Tumorigenicity was assessed by subcutaneous injection of 1610 7 cells resuspended in 0.2 ml of DMEM, into the¯anks of 4-to 6-week-old nude mice (two sites per mouse). Tumor formation was monitored once a week for 5 months. Animals were sacri®ced when tumor size reached *2.5 cm in diameter.
Transactivation assay CCL13 cells were plated 1 day prior to transfection at a density of 3.5610 5 cells in 35 mn plates and cotransfected with 0.3 mg of reporter vector (pSV2-Luc (de Wet et al., 1987) containing the luciferase gene under the control of the SV40 enhancer/promoter) and 3 mg of the dierent activators (S2A, S2Am, PreS2/S t , dCycA, the empty expression plasmid pOPRSVICAT (Neo) and as positive control pRc-CMV-X coding for HBx transactivator). Luciferase activity was measured in 100 mg of protein extract using standard protocols.
Immuno¯uorescence and confocal analysis COS cells were transfected with GFP constructs and grown on coverslips for 40 h. After medium removal, cells were washed three times with PBS and directly mounted for conventional microscopy analysis. For confocal analysis, cells were ®xed with 3.7% formaldehyde in PBS for 10 min, permeabilized with 0.2% Triton X-100 in PBS for 5 min and labeled with 7-aminoactinomycin D (Sigma). Cells were also labeled with two antibodies that recognize the endoplasmic reticulum (ER): anti-ER (Ash et al., 1977) and anti-PDI (Huovila et al., 1992) , that were visualized with TRITC. Coverslips were mounted with Mowiol and analysed on a confocal microscope CLSM (Leica), with an argon-krypton laser (488 nm, 568 nm); for FITC a narrow-band ®lter centered on 535 nm+8 nm, line 488 nm; and for TRITC a long wave pass ®lter RG 590 nm, line 568 nm were used.
Cell-free transcription, translation and translocation
In vitro transcription-translation, either in the presence or absence of intact dog pancreas rough microsomes and a tripeptide competitor of N-linked glycosylation (AcAsnTyr-Thr) was performed as described (Chuck and Lingappa, 1992) . In protease protection assays translation reactions were treated with proteinase K at a ®nal concentration of 0.2 ± 0.5 mg/ml either in the presence or in the absence of 1% Triton X-100 (a nonionic detergent used to disrupt the lipid bilayer). Membrane sedimentation through a 0.25 M sucrose cushion containing 2 mM PMSF at 20 p.s.i. for 3 min in a Beckman airfuge was performed after inactivation of protease with 2 mM PMSF. Equal proportions of the supernatant and the pellet fractions were subjected to SDS ± PAGE and analysed by autoradiography.
